



8 July 2014

Company Announcements Office
Australian Securities Exchange

Appendix 3Y Change of Director's Interest Notice

Attached is an Appendix 3Y- Change of Director's Interest Notice in respect of changes in the relevant interests in securities held by Dr Ron Weinberger, Executive Director of Nanosonics.

Additional information about the nature of the changes in securities held by Dr Weinberger is provided below.

Dr Weinberger has exercised 200,000 market priced options (\$0.556) that were originally granted in July 2010 and were due to lapse on 19 July 2014. In order to fund the exercise of these options Dr Weinberger has sold 148,000 shares that were acquired as a result of the exercise.

For more information please contact:

Michael Kavanagh, CEO and President or McGregor Grant, CFO, on +612 8063 1600

Rebecca Wilson, Investor and media relations, Buchan Consulting on +613 9866 4722 / 0401 018 828

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| | |
|----------------|---------------------------|
| Name of entity | Nanosonics Limited |
| ABN | 11 095 076 896 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---------------------|-----------------------------------|
| Name of Director | Dr Ronald Peter Weinberger |
| Date of last notice | 4 March 2014 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|--|--|
| Direct or indirect interest | a) Indirect Interest b) Indirect Interest c) Indirect Interest |
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | a) Shares held under the Nanosonics Deferred Employee Share Plan b) Options c) Performance Rights |
| Date of change | 4 July 2014 |
| No. of securities held prior to change | a) 68,607 Ordinary Shares held under the Nanosonics Deferred Employee Share Plan b) 200,000 Options held in the Nanosonics Employee Share Option Plan c) 1,354,818 Performance Rights held in the Nanosonics Employee Share Option Plan. |

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

| | |
|--|---|
| Class | a) Ordinary Shares b) Options c) Performance Rights |
| Number acquired | 200,000 Ordinary Shares |
| Number disposed | 200,000 Options 148,000 Ordinary Shares (sold to fund the above exercise of options) |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | NIL |
| No. of securities held after change | a) 68,607 (Indirect) Ordinary Shares held in the Nanosonics Deferred Employee Share Plan b) 1,354,818 (Indirect) Performance Rights held in the Nanosonics Employee Share Option Plan. c) 52,000 (Direct) Ordinary Shares |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | a) Exercise of Options under the terms and conditions of the Nanosonics Employee Share Option Plan. b) Issue and sale of Ordinary Shares |

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|-----|
| Detail of contract | N/A |
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

| | |
|---|--|
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |

Part 3 – ⁺Closed period

| | |
|---|--|
| Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required? | |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

Director: Dr Ronald Weinberger
Date: 8 July 2014

⁺ See chapter 19 for defined terms.